121- de Almeida PW, Melo MB, Lima Rde F, Gavioli M, Santiago NM, Greco L, et al. Beneficial
effects of angiotensin-(1-7) against deoxycorticosterone acetate-induced diastolic dysfunc-
tion occur independently of changes in blood pressure. Hypertension. 2015;66(2):389–95. - Giani JF, Munoz MC, Mayer MA, Veiras LC, Arranz C, Taira CA, et al. Angiotensin-(1-7)
improves cardiac remodeling and inhibits growth-promoting pathways in the heart of
fructose- fed rats. Am J Physiol Heart Circ Physiol. 2010;298(3):H1003–13. - Katovich MJ, Grobe JL, Raizada MK. Angiotensin-(1-7) as an antihypertensive, antifibrotic
target. Curr Hypertens Rep. 2008;10(3):227–32. - Singh N, Joshi S, Guo L, Baker MB, Li Y, Castellano RK, et al. ACE2/Ang-(1-7)/Mas
axis stimulates vascular repair-relevant functions of CD34+ cells. Am J Physiol Heart Circ
Physiol. 2015;309(10):H1697–707. - Dilauro M, Burns KD. Angiotensin-(1-7) and its effects in the kidney. ScientificWorldJournal.
2009;9:522–35. - Patel VB, Takawale A, Ramprasath T, Das SK, Basu R, Grant MB, et al. Antagonism of
angiotensin 1–7 prevents the therapeutic effects of recombinant human ACE2. J Mol Med
(Berlin, Germany). 2015;93(9):1003–13. - Tom B, Dendorfer A, Danser AH. Bradykinin, angiotensin-(1-7), and ACE inhibitors: how do
they interact? Int J Biochem Cell Biol. 2003;35(6):792–801. - Bjorkholt Andersen L, Herse F, Christesen HT, Dechend R, Muller D. PP005. Vitamin D
depletion aggravates hypertension in transgenic rats. Pregnancy Hypertens. 2013;3(2):69. - Garcia IM, Altamirano L, Mazzei L, Fornes M, Cuello-Carrion FD, Ferder L, et al. Vitamin D
receptor-modulated Hsp70/AT1 expression may protect the kidneys of SHRs at the structural
and functional levels. Cell Stress Chaperones. 2014;19(4):479–91. - Xue B, Pamidimukkala J, Lubahn DB, Hay M. Estrogen receptor-alpha mediates estrogen
protection from angiotensin II-induced hypertension in conscious female mice. Am J Physiol
Heart Circ Physiol. 2007;292(4):H1770–6. - Wei LH, Huang XR, Zhang Y, Li YQ, Chen HY, Heuchel R, et al. Deficiency of Smad7
enhances cardiac remodeling induced by angiotensin II infusion in a mouse model of hyper-
tension. PLoS One. 2013;8(7):e70195. - Qiu Y, Tao L, Lei C, Wang J, Yang P, Li Q, et al. Downregulating p22phox ameliorates
inflammatory response in angiotensin II-induced oxidative stress by regulating MAPK and
NF-kappaB pathways in ARPE-19 cells. Sci Rep. 2015;5:14362. - Tain YL, Sheen JM, Yu HR, Chen CC, Tiao MM, Hsu CN, et al. Maternal melatonin therapy
rescues prenatal dexamethasone and postnatal high-fat diet induced programmed hyperten-
sion in male rat offspring. Front Physiol. 2015;6:377. - Scholkens BA. Kinins in the cardiovascular system. Immunopharmacology. 1996;
33(1–3):209–16. - Natarajan AR, Eisner GM, Armando I, Browning S, Pezzullo JC, Rhee L, et al. The renin-
angiotensin and renal dopaminergic systems interact in normotensive humans. J Am Soc
Nephrol JASN. 2016;27(1):265–79. - Jose PA, Eisner GM, Felder RA. Dopaminergic defect in hypertension. Pediatr Nephrol
(Berlin, Germany). 1993;7(6):859–64. - Sakamoto T, Chen C, Lokhandwala MF. Lack of renal dopamine production during acute
volume expansion in Dahl salt-sensitive rats. Clin Exp Hypertens (New York, NY: 1993).
1994;16(2):197–206. - Armando I, Villar VA, Jose PA. Dopamine and renal function and blood pressure regulation.
Compr Physiol. 2011;1(3):1075–117. - Choi MR, Kouyoumdzian NM, Rukavina Mikusic NL, Kravetz MC, Roson MI, Rodriguez
Fermepin M, et al. Renal dopaminergic system: pathophysiological implications and clinical
perspectives. World J Nephrol. 2015;4(2):196–212. - Sanada H, Jose PA, Hazen-Martin D, Yu PY, Xu J, Bruns DE, et al. Dopamine-1 receptor cou-
pling defect in renal proximal tubule cells in hypertension. Hypertension. 1999;33(4):1036–42. - Hussain T, Kansra V, Lokhandwala MF. Renal dopamine receptor signaling mechanisms in
spontaneously hypertensive and Fischer 344 old rats. Clin Exp Hypertens (New York, NY:
1993). 1999;21(1–2):25–36.
7 Pathophysiological Insights in Resistant Hypertension